Clinical trials: Fibroblast Activation Protein Inhibitor
Advanced Chronic Liver Disease, Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
The purpose of this study is to assess the pharmacokinetics (PK) and safety of AZD2389 when administered alone and in combination with quinidine in healthy participants.
- Trial name
- NCT06974565
- Testing
- AZD2389, Quinidine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Malignant Tumor, Positron Emission Tomography
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
Adding targeted covalent radiopharmaceutical (TCR) moiety to fibroblast activation protein inhibitor (FAPI) can increase tumor uptake and tumor retention in pre-clinical studies.
- Conditions
- Malignant Tumor, Positron Emission Tomography, Fibroblast Activation Protein Inhibitor
- Trial name
- NCT06084767
- Testing
- 68Ga-TCR-FAPI PET/CT
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Healthy Participants
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.
- Trial name
- NCT06846528
- Testing
- AZD2389, Itraconazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Fibroblast Activation Protein Inhibitor, PET/CT
68Ga-FAPI PET/CT in Malignant Tumors
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms.
- Conditions
- Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm
- Trial name
- NCT05034146
- Testing
- 68Ga-FAPI, PET/CT
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Heart Failure With Preserved Ejection Fraction
A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
- Trial name
- NCT07083011
- Testing
- 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
PASC Post Acute Sequelae of COVID 19, Long COVID
From Inflammation to Remodelling Towards Personalized Diagnosis in Post-acute Sequelae of COVID-19
Rationale: The diagnosis and pathogenesis of long COVID remains unknown. We have previously shown that [68Ga]FAPI Positron Emission Tomography-Computed Tomography (PET/CT) imaging shows potential for diagnosis and molecular…
- Conditions
- PASC Post Acute Sequelae of COVID 19, Long COVID, Long Covid-19, PASC
- Trial name
- LIBERATE (NCT06911476)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen